Alpha 2.0
Login Register
» Articles » PMID: 21633602

Lapatinib-induced Hepatitis: a Case Report

Overview
Journal World J Gastroenterol
Publisher Baishideng Publishing Group
Specialty Gastroenterology
Date 2011 Jun 3
PMID 21633602
Citations 7
Authors
Stavros Peroukides
Thomas Makatsoris
Angelos Koutras
Athanasios Tsamandas
Adimchi Onyenadum
Chryssoula Labropoulou-Karatza
Haralabos Kalofonos
Affiliations
Soon will be listed here.
Abstract

Lapatinib is an inhibitor of the tyrosine kinases of human epidermal growth factor receptor type 2 (HER2) and epidermal growth factor receptor type 1, with clinical activity in HER2-positive metastatic breast cancer. We present here a 60 year-old patient with metastatic breast cancer who presented with jaundice and increased serum aminotransferase levels and who had been treated with lapatinib for the previous 14 days. Laboratory tests excluded other causes of acute liver injury. Liver biopsy revealed lesions compatible with drug-induced hepatotoxicity. Bilirubin and liver enzymes returned to normal within three months of lapatinib discontinuation. Lapatinib should be included among the causes of drug-induced hepatitis.

Citing Articles

Management of hepatotoxicity of chemotherapy and targeted agents.

Mudd T, Guddati A Am J Cancer Res. 2021; 11(7):3461-3474.

PMID: 34354855 PMC: 8332851.

Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient.

Zhang Z, Xu L, Qin N, Zhang J, Xiang Q, Liu Q Thorac Cancer. 2021; 12(12):1912-1916.

PMID: 33957015 PMC: 8201538. DOI: 10.1111/1759-7714.13986.

Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells.

Roos N, Aliu D, Bouitbir J, Krahenbuhl S Front Pharmacol. 2020; 11:944.

PMID: 32694997 PMC: 7339965. DOI: 10.3389/fphar.2020.00944.

Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.

Bissada J, Truong V, Abouda A, Wines K, Crouch R, Jackson K Drug Metab Dispos. 2019; 47(11):1257-1269.

PMID: 31492693 PMC: 6815940. DOI: 10.1124/dmd.119.088823.

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.

Iyengar N, Fornier M, Sugarman S, Theodoulou M, Troso-Sandoval T, DAndrea G Clin Breast Cancer. 2015; 16(2):87-94.

PMID: 26454612 PMC: 4968930. DOI: 10.1016/j.clbc.2015.09.009.

References
1.
Rudin C, Liu W, Desai A, Karrison T, Jiang X, Janisch L . Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008; 26(7):1119-27. PMC: 5846189. DOI: 10.1200/JCO.2007.13.1128. View
2.
Burris 3rd H, Hurwitz H, Dees E, Dowlati A, Blackwell K, ONeil B . Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005; 23(23):5305-13. DOI: 10.1200/JCO.2005.16.584. View
3.
Tevaarwerk A, Kolesar J . Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2010; 31 Pt 2:2332-48. DOI: 10.1016/j.clinthera.2009.11.029. View
4.
Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View
5.
Geyer C, Forster J, Lindquist D, Chan S, Romieu C, Pienkowski T . Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355(26):2733-43. DOI: 10.1056/NEJMoa064320. View